The nation of Zimbabwe has declined a substantial American health deal valued at 367 million US dollars (£272m) spanning five years due to the United States' insistence on confidential information.
The decision became public after a government memo dated December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
A government spokesman has since stated that the United States was demanding access to biological samples for research and commercial purposes but was not willing to guarantee the resulting advantages from future vaccines.
"We are forced to start the challenging and unfortunate task of ending our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had furnished over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for continued negotiations to find a agreement acceptable to both sides so the country's critical HIV programme can continue.
Wider Background
This rejection comes after a comparable case in Kenya, where a high court suspended a similar health funding agreement following legal challenges were raised about the security of citizens' health data.
After resuming office last year, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
The agency had managed assistance for the American government, but Trump argued its spending was "wasteful" and his government was seeking direct bilateral agreements to enhance transparency and accountability.
As per reports, 16 African countries have so far agreed to these new health pacts, representing over $18.3bn in committed funds.
Details of the Declined Deal
This assistance for Zimbabwe would have supported "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership would have delivered significant advantages for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy via US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to surrender its biological resources and data for a long time, without any corresponding promise of access to any scientific breakthroughs – like new medicines or tests – that could result from that provided information," Mangwana explained.
"Put simply, our country would supply the basic resources for medical research without any assurance that the resulting innovations would be accessible to our population should a future pandemic arise."
Sovereignty and Global Health
He also said that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral health agreements were upending systems already set up through the international health agency.
Mangwana cited its Pandemic Benefit-Sharing system designed to deal with future pandemics.
"This framework is designed to guarantee that when a country contributes its information, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as opposition to America," he added.
"We encourage continued dialogue with our American counterparts on how subsequent collaboration could be structured in a manner that honours the independence and dignity of each country."
Medical Community Response
A leading public health body said it understood the official position, but recommended that negotiations must proceed since a large portion of the nation's Aids initiatives relied on foreign aid.
"In cases where specific concerns arise, including those involving data governance or implementation frameworks, these can often be resolved via technical clarification and negotiated safeguards," it added.
The halted deal underscores the complex tensions between accepting much-needed international aid and safeguarding local interests in an increasingly data-driven world.